OMERACT Filter 2.1 Instrument Selection for Physical Function Domain in Psoriatic Arthritis: Provisional Endorsement for HAQ-DI and SF-36 PF

Ying-Ying Leung; Ana-Maria Orbai; Pil Hojgaard; Richard Holland; Ashish J Mathew; Niti Goel; Jeffrey Chau; William Tillett; Christine Lindsay; Alexis Ogdie; Laura C Coates; Dafna D Gladman; Robin Christensen; Philip Mease; Vibeke Strand

doi:10.1016/j.semarthrit.2021.07.014

OMERACT Filter 2.1 Instrument Selection for Physical Function Domain in Psoriatic Arthritis: Provisional Endorsement for HAQ-DI and SF-36 PF

Ying-Ying Leung, Ana-Maria Orbai, Pil Hojgaard, Richard Holland, Ashish J Mathew, Niti Goel, Jeffrey Chau, William Tillett, Christine Lindsay, Alexis Ogdie, Laura C Coates, Dafna D Gladman, Robin Christensen, Philip Mease, Vibeke Strand

Research output: Contribution to journal › Article › peer-review

7 Citations (SciVal)

41 Downloads (Pure)

Abstract

OBJECTIVES: Physical function is one of the core domains to be measured in all trials in psoriatic arthritis (PsA). We aimed to evaluate two instruments for physical function in PsA: The Health Assessment Questionnaire-disability index (HAQ-DI) and the physical functioning subscale of the Medical Outcome Survey Short-Form 36 items (SF-36 PF).

METHODS: We followed guidelines set out by the OMERACT Filter 2.1. A working group was formed to evaluate each instrument for domain match and feasibility to reach consensus. Two systematic literature reviews (SLRs) were conducted to identify the relevant articles supporting measurement properties of both instruments. Five additional measurement properties were appraised: construct validity, test-retest reliability, longitudinal construct validity, clinical trial discrimination, and threshold of meaning. New evidence was synthesized to fill the gap. Data were presented to the OMERACT technical advisory group (TAG) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) community for endorsement.

RESULTS: The results for seven measurement properties for HAQ-DI and SF-36 PF were presented in Summary of Measurement Property (SOMP) tables. The working group proposed "Provisional Endorsement" for both instruments. The body of evidence was approved by the OMERACT TAG. In two Delphi exercises among GRAPPA members, HAQ-DI received 93.9% and 97.5% endorsement votes, while that for SF-36 PF were 86.7% and 77.3%.

CONCLUSION: Both HAQ-DI and SF-36 PF were provisionally endorsed for the measurement of physical function in PsA trials, using the OMERACT Filter 2.1.

Original language	English
Pages (from-to)	1117-1124
Number of pages	8
Journal	Seminars in Arthritis and Rheumatism
Volume	51
Issue number	5
Early online date	24 Jul 2021
DOIs	https://doi.org/10.1016/j.semarthrit.2021.07.014
Publication status	Published - Oct 2021

Bibliographical note

Funding Information:
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503 Cores A and D, and P30-AR070254, Cores A and B). PH and RC (The Parker Institute, Bispebjerg and Frederiksberg Hospital) is supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). LCC is funded by a National Institute for Health Research Clinician Scientist award, and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). AO is funded by NIH/NIAMS R01 AR072363.

Funding Information:
We would like to thank Lara Maxwell and Dorcas Beaton, members of the OMERACT TAG in valuable advices and critically reviewed the body of evidence in this project. We thank all GRAPPA PRPs who participated in various workstreams. We thank all the GRAPPA members who read through the evidence and participated in the Delphi exercises for endorsement.

Publisher Copyright:
© 2021 Elsevier Inc.

ASJC Scopus subject areas

Rheumatology
Anesthesiology and Pain Medicine

Access to Document

10.1016/j.semarthrit.2021.07.014

HAQ_and_SF_PF_endorsed_R1.PDFAccepted author manuscript, 344 KBLicence: CC BY-NC-ND

Cite this

Leung, Y.-Y., Orbai, A.-M., Hojgaard, P., Holland, R., Mathew, A. J., Goel, N., Chau, J., Tillett, W., Lindsay, C., Ogdie, A., Coates, L. C., Gladman, D. D., Christensen, R., Mease, P., & Strand, V. (2021). OMERACT Filter 2.1 Instrument Selection for Physical Function Domain in Psoriatic Arthritis: Provisional Endorsement for HAQ-DI and SF-36 PF. Seminars in Arthritis and Rheumatism, 51(5), 1117-1124. https://doi.org/10.1016/j.semarthrit.2021.07.014

Leung, Y-Y, Orbai, A-M, Hojgaard, P, Holland, R, Mathew, AJ, Goel, N, Chau, J, Tillett, W, Lindsay, C, Ogdie, A, Coates, LC, Gladman, DD, Christensen, R, Mease, P & Strand, V 2021, 'OMERACT Filter 2.1 Instrument Selection for Physical Function Domain in Psoriatic Arthritis: Provisional Endorsement for HAQ-DI and SF-36 PF', Seminars in Arthritis and Rheumatism, vol. 51, no. 5, pp. 1117-1124. https://doi.org/10.1016/j.semarthrit.2021.07.014

@article{dcd350b1631d40d98d10eec0f109b4ea,

title = "OMERACT Filter 2.1 Instrument Selection for Physical Function Domain in Psoriatic Arthritis: Provisional Endorsement for HAQ-DI and SF-36 PF",

abstract = "OBJECTIVES: Physical function is one of the core domains to be measured in all trials in psoriatic arthritis (PsA). We aimed to evaluate two instruments for physical function in PsA: The Health Assessment Questionnaire-disability index (HAQ-DI) and the physical functioning subscale of the Medical Outcome Survey Short-Form 36 items (SF-36 PF).METHODS: We followed guidelines set out by the OMERACT Filter 2.1. A working group was formed to evaluate each instrument for domain match and feasibility to reach consensus. Two systematic literature reviews (SLRs) were conducted to identify the relevant articles supporting measurement properties of both instruments. Five additional measurement properties were appraised: construct validity, test-retest reliability, longitudinal construct validity, clinical trial discrimination, and threshold of meaning. New evidence was synthesized to fill the gap. Data were presented to the OMERACT technical advisory group (TAG) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) community for endorsement.RESULTS: The results for seven measurement properties for HAQ-DI and SF-36 PF were presented in Summary of Measurement Property (SOMP) tables. The working group proposed {"}Provisional Endorsement{"} for both instruments. The body of evidence was approved by the OMERACT TAG. In two Delphi exercises among GRAPPA members, HAQ-DI received 93.9% and 97.5% endorsement votes, while that for SF-36 PF were 86.7% and 77.3%.CONCLUSION: Both HAQ-DI and SF-36 PF were provisionally endorsed for the measurement of physical function in PsA trials, using the OMERACT Filter 2.1.",

author = "Ying-Ying Leung and Ana-Maria Orbai and Pil Hojgaard and Richard Holland and Mathew, {Ashish J} and Niti Goel and Jeffrey Chau and William Tillett and Christine Lindsay and Alexis Ogdie and Coates, {Laura C} and Gladman, {Dafna D} and Robin Christensen and Philip Mease and Vibeke Strand",

note = "Funding Information: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503 Cores A and D, and P30-AR070254, Cores A and B). PH and RC (The Parker Institute, Bispebjerg and Frederiksberg Hospital) is supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). LCC is funded by a National Institute for Health Research Clinician Scientist award, and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). AO is funded by NIH/NIAMS R01 AR072363. Funding Information: We would like to thank Lara Maxwell and Dorcas Beaton, members of the OMERACT TAG in valuable advices and critically reviewed the body of evidence in this project. We thank all GRAPPA PRPs who participated in various workstreams. We thank all the GRAPPA members who read through the evidence and participated in the Delphi exercises for endorsement. Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2021",

month = oct,

doi = "10.1016/j.semarthrit.2021.07.014",

language = "English",

volume = "51",

pages = "1117--1124",

journal = "Seminars in Arthritis and Rheumatism",

issn = "0049-0172",

publisher = "W.B. Saunders",

number = "5",

}

TY - JOUR

T1 - OMERACT Filter 2.1 Instrument Selection for Physical Function Domain in Psoriatic Arthritis

T2 - Provisional Endorsement for HAQ-DI and SF-36 PF

AU - Leung, Ying-Ying

AU - Orbai, Ana-Maria

AU - Hojgaard, Pil

AU - Holland, Richard

AU - Mathew, Ashish J

AU - Goel, Niti

AU - Chau, Jeffrey

AU - Tillett, William

AU - Lindsay, Christine

AU - Ogdie, Alexis

AU - Coates, Laura C

AU - Gladman, Dafna D

AU - Christensen, Robin

AU - Mease, Philip

AU - Strand, Vibeke

N1 - Funding Information: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503 Cores A and D, and P30-AR070254, Cores A and B). PH and RC (The Parker Institute, Bispebjerg and Frederiksberg Hospital) is supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). LCC is funded by a National Institute for Health Research Clinician Scientist award, and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). AO is funded by NIH/NIAMS R01 AR072363. Funding Information: We would like to thank Lara Maxwell and Dorcas Beaton, members of the OMERACT TAG in valuable advices and critically reviewed the body of evidence in this project. We thank all GRAPPA PRPs who participated in various workstreams. We thank all the GRAPPA members who read through the evidence and participated in the Delphi exercises for endorsement. Publisher Copyright: © 2021 Elsevier Inc.

PY - 2021/10

Y1 - 2021/10

N2 - OBJECTIVES: Physical function is one of the core domains to be measured in all trials in psoriatic arthritis (PsA). We aimed to evaluate two instruments for physical function in PsA: The Health Assessment Questionnaire-disability index (HAQ-DI) and the physical functioning subscale of the Medical Outcome Survey Short-Form 36 items (SF-36 PF).METHODS: We followed guidelines set out by the OMERACT Filter 2.1. A working group was formed to evaluate each instrument for domain match and feasibility to reach consensus. Two systematic literature reviews (SLRs) were conducted to identify the relevant articles supporting measurement properties of both instruments. Five additional measurement properties were appraised: construct validity, test-retest reliability, longitudinal construct validity, clinical trial discrimination, and threshold of meaning. New evidence was synthesized to fill the gap. Data were presented to the OMERACT technical advisory group (TAG) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) community for endorsement.RESULTS: The results for seven measurement properties for HAQ-DI and SF-36 PF were presented in Summary of Measurement Property (SOMP) tables. The working group proposed "Provisional Endorsement" for both instruments. The body of evidence was approved by the OMERACT TAG. In two Delphi exercises among GRAPPA members, HAQ-DI received 93.9% and 97.5% endorsement votes, while that for SF-36 PF were 86.7% and 77.3%.CONCLUSION: Both HAQ-DI and SF-36 PF were provisionally endorsed for the measurement of physical function in PsA trials, using the OMERACT Filter 2.1.

AB - OBJECTIVES: Physical function is one of the core domains to be measured in all trials in psoriatic arthritis (PsA). We aimed to evaluate two instruments for physical function in PsA: The Health Assessment Questionnaire-disability index (HAQ-DI) and the physical functioning subscale of the Medical Outcome Survey Short-Form 36 items (SF-36 PF).METHODS: We followed guidelines set out by the OMERACT Filter 2.1. A working group was formed to evaluate each instrument for domain match and feasibility to reach consensus. Two systematic literature reviews (SLRs) were conducted to identify the relevant articles supporting measurement properties of both instruments. Five additional measurement properties were appraised: construct validity, test-retest reliability, longitudinal construct validity, clinical trial discrimination, and threshold of meaning. New evidence was synthesized to fill the gap. Data were presented to the OMERACT technical advisory group (TAG) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) community for endorsement.RESULTS: The results for seven measurement properties for HAQ-DI and SF-36 PF were presented in Summary of Measurement Property (SOMP) tables. The working group proposed "Provisional Endorsement" for both instruments. The body of evidence was approved by the OMERACT TAG. In two Delphi exercises among GRAPPA members, HAQ-DI received 93.9% and 97.5% endorsement votes, while that for SF-36 PF were 86.7% and 77.3%.CONCLUSION: Both HAQ-DI and SF-36 PF were provisionally endorsed for the measurement of physical function in PsA trials, using the OMERACT Filter 2.1.

UR - http://www.scopus.com/inward/record.url?scp=85112675854&partnerID=8YFLogxK

U2 - 10.1016/j.semarthrit.2021.07.014

DO - 10.1016/j.semarthrit.2021.07.014

M3 - Article

C2 - 34392975

SN - 0049-0172

VL - 51

SP - 1117

EP - 1124

JO - Seminars in Arthritis and Rheumatism

JF - Seminars in Arthritis and Rheumatism

IS - 5

ER -

OMERACT Filter 2.1 Instrument Selection for Physical Function Domain in Psoriatic Arthritis: Provisional Endorsement for HAQ-DI and SF-36 PF

Abstract

Bibliographical note

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this